contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


senzagen-obtains-expanded-oecd-approval-for-gardrskin-further-strengthens-position-in-non-animal-regulatory-testing

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund. 

SenzaGen

SenzaGen’s non-animal test method GARD®skin, which has been approved since 2022 under OECD Test Guideline TG 442E, has now also been included in the newly introduced OECD TG 497. This international...

<div class="mfn-preamble">SenzaGen’s non-animal test method GARD®skin, which has been approved since 2022 under OECD Test Guideline TG 442E, has now also been included in the newly introduced OECD TG 497. This international guideline describes how different non-animal methods can be combined in regulatory testing to assess whether chemicals may cause skin allergies and how potent they are. The inclusion is expected to increase demand from companies in the chemical and cosmetics industries.</div><div class="mfn-body">GARD®skin is based on genomics and machine learning and delivers highly reliable and accurate decision-making data. With this inclusion in TG 497, the industry gains improved regulatory access to a high-performing and versatile method that works for both pure chemicals and more complex substances and mixtures that have traditionally been difficult to assess. Since 2022, GARD®skin has also been approved under OECD Test Guideline TG 442E.“This expanded approval of GARD®skin is an important step in our commercial development. It opens the door to broader use of our method and is expected to drive increased interest from several key customer segments. We bring important new value to regulatory testing, especially when it comes to complex mixtures and difficult-to-test substances, a need we can meet but which previously has lacked effective solutions,” says Peter Nählstedt, CEO and Group President of SenzaGen.</div><div class="mfn-footer mfn-about mfn-59f0b3757870">About us<hr>SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit:&nbsp;www.senzagen.com.SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.&nbsp;</div><div class="mfn-footer mfn-contacts mfn-ba9271758839">Contacts<hr>Peter Nählstedt, President and CEO, SenzaGen AB Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31 Tina Dackemark Lawesson, VP Marketing &amp; Communications Email:&nbsp;<a rel="noopener" href="mailto:tina.lawesson@senzagen.com">tina.lawesson@senzagen.com</a>&nbsp;| Mobile: +46 708 20 29 44</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/fab1d1c6-68a2-49e1-ad41-06511e9a416e/senzagen-obtains-expanded-oecd-approval-for-gard-r-skin-further-strengthens-position-in-non-animal-regulatory-testing.pdf" class="mfn-generated mfn-primary">SenzaGen obtains expanded OECD approval for GARD®skin – further strengthens position in non-animal regulatory testing</a></div>

SenzaGen obtains expanded OECD approval for GARD®skin – further strengthens position in non-animal regulatory testing